Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559871 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by Juvantia Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT00559871: Completed Phase 2 study of Parkinson's Disease, sponsored by Juvantia Pharma.
NCT00559871 is a Phase 2 study of Parkinson's Disease that has completed, run by Juvantia Pharma. The registered enrollment target is 180 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00559871, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Juvantia Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.
Conditions Studied
Interventions
- DRUG fipamezole
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorder Center - Boca Raton
- Sunrise Clinical Research - Hollywood
- Pharmax Research Clinic - Miami
- University of Miami - Miami
- Collier Neurological Clinic - Naples
- University of South Florida, Parkinson's Disease and Movement Center - Tampa
California
- Parkinson and Movement Disorder Institute - Fountain Valley
- University of California Irvine - Irvine
- Coastal Neurological Medicine Group - La Jolla
Alabama
- University of Alabama at Birmingham - Birmingham
- Neurology Clinic PC - Northport
Georgia
- Emory Healthcare - Atlanta
- Medical College of Georgia - Augusta
Arizona
- University of Arizona Health Sciences Center - Tucson
Colorado
- Colorado Neurological Institute - Englewood
Illinois
- Rush University Medical Center - Chicago
Kansas
- Parkinson Disease Center - University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00559871 record still lists
NCT00559871 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which fipamezole is the first listed.
NCT00559871 names 20 study sites across 11 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00559871 about?
NCT00559871 is a clinical study titled "Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease". The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.
What is the current status of trial NCT00559871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2007-10. Estimated completion is 2009-05.
What conditions does trial NCT00559871 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00559871?
The interventions under investigation include: fipamezole (DRUG).
Who is sponsoring clinical trial NCT00559871?
This trial is sponsored by Juvantia Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00559871 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00559871's enrollment target sits among peer trials
180 38th of 158 higher than 120 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia